Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valerie Quarmby

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Bioanalysis|June 9, 2011
Free versus total ligand-binding assays: points to consider in biotherapeutic drug developmentJihong Yang, Valerie Quarmby
Journal of Immunological Methods|December 4, 2001
Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patientsRegina E Chestnut, Valerie Quarmby
Nature Reviews. Drug Discovery|October 18, 2024
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeuticsPaul J Carter, Valerie Quarmby
Journal of Immunological Methods|April 6, 2010
Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interferenceKrista M McCutcheon, Valerie Quarmby, An Song
Expert Review of Proteomics|September 11, 2018
MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arenaValerie Quarmby, Qui T Phung, Jennie R Lill
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2010
Clinical immunogenicity specificity assessments: a platform evaluationKun Peng, Ketevan Siradze, Valerie Quarmby, et al.
Clinical and Translational Science|March 9, 2022
Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitroChristian Hammer, Jane Ruppel, Lynn Kamen, et al.
Biotechnology and Bioengineering|May 27, 2015
Host cell proteins in biotechnology-derived products: A risk assessment frameworkChristina L Zuch de Zafra, Valerie Quarmby, Kathleen Francissen, et al.
The AAPS Journal|April 1, 2014
New FDA draft guidance on immunogenicityAshwin Parenky, Heather Myler, Lakshmi Amaravadi, et al.
Nature Biotechnology|April 8, 2015
The quintessence of immunogenicity reporting for biotherapeuticsGopi Shankar, Steven Arkin, Viswanath Devanarayan, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Bioanalysis|June 9, 2011
Free versus total ligand-binding assays: points to consider in biotherapeutic drug developmentJihong Yang, Valerie Quarmby
Journal of Immunological Methods|December 4, 2001
Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patientsRegina E Chestnut, Valerie Quarmby
Nature Reviews. Drug Discovery|October 18, 2024
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeuticsPaul J Carter, Valerie Quarmby
Journal of Immunological Methods|April 6, 2010
Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interferenceKrista M McCutcheon, Valerie Quarmby, An Song
Expert Review of Proteomics|September 11, 2018
MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arenaValerie Quarmby, Qui T Phung, Jennie R Lill
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2010
Clinical immunogenicity specificity assessments: a platform evaluationKun Peng, Ketevan Siradze, Valerie Quarmby, et al.
Clinical and Translational Science|March 9, 2022
Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitroChristian Hammer, Jane Ruppel, Lynn Kamen, et al.
Biotechnology and Bioengineering|May 27, 2015
Host cell proteins in biotechnology-derived products: A risk assessment frameworkChristina L Zuch de Zafra, Valerie Quarmby, Kathleen Francissen, et al.
The AAPS Journal|April 1, 2014
New FDA draft guidance on immunogenicityAshwin Parenky, Heather Myler, Lakshmi Amaravadi, et al.
Nature Biotechnology|April 8, 2015
The quintessence of immunogenicity reporting for biotherapeuticsGopi Shankar, Steven Arkin, Viswanath Devanarayan, et al.
Pageof 4